Where American Men Live May Shape Their Odds of Surviving Prostate Cancer, New Study Reveals

New federal data analyzed by the Daily Mail suggests that where American men live may play a major role in whether they survive prostate cancer, with sharp regional differences emerging in diagnosis rates, access to screening and mortality.

The analysis found that parts of the South, including Mississippi, Louisiana and Georgia, record some of the country's highest prostate cancer death rates. Mississippi reports nearly 25 prostate cancer deaths per 100,000 men, while Louisiana and Georgia also rank among the highest for diagnoses and mortality.

Researchers and public health experts point to several overlapping factors, including poverty, lack of insurance coverage, fewer primary care physicians and limited access to specialists. In many rural communities, patients can face long travel distances for imaging or follow-up care after abnormal PSA blood tests, often delaying diagnosis until cancers are more advanced.

By contrast, Northeastern states such as New Jersey, Maryland and New York report comparatively high diagnosis rates but lower death rates, a trend researchers largely attribute to broader access to healthcare and more widespread screening. New Jersey, for example, records nearly 147 prostate cancer cases per 100,000 men but maintains one of the nation's lower mortality rates, at roughly 16 deaths per 100,000.

The report cited concerns in Louisiana's "Cancer Alley," an industrial corridor associated with elevated cancer risks, as well as studies linking nitrate contamination and pesticide exposure in Midwestern farming regions to more aggressive forms of prostate cancer. A long-term Agricultural Health Study cited in the report found that men exposed to high nitrate levels in drinking water faced a 22% higher risk of developing aggressive disease.

Some states are also seeing rapidly rising diagnosis rates. Vermont's prostate cancer rate is increasing by more than 6% annually, according to NIH data cited by the Daily Mail, while Alaska, Iowa and Wisconsin are also recording notable increases.

The findings come as medical experts warn that delays affecting federal preventive care recommendations could complicate access to cancer screening nationwide. Reuters reported in April that the U.S. Preventive Services Task Force, which helps determine which screenings insurers must cover at no cost, has not met in more than a year after several planned meetings were canceled.

The panel had been reviewing updated recommendations for prostate cancer screening. Without new guidance, some experts say uncertainty around preventive care and insurance coverage could persist.

"The task force is meant to be objective," Dr. Alex Krist, a former chair of the panel, told Reuters. "Primary care is kind of struggling with what we should do."